Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 82,736 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 82,736 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $64.97, for a total value of $5,375,357.92. Following the completion of the sale, the director owned 1,787,306 shares of the company’s stock, valued at $116,121,270.82. This trade represents a 4.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Liquidia Stock Up 3.3%

LQDA stock opened at $63.90 on Tuesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The stock has a market capitalization of $5.68 billion, a P/E ratio of 456.46 and a beta of 0.57. The business has a 50-day moving average of $47.32 and a 200-day moving average of $39.87. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $66.78.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.Liquidia’s quarterly revenue was up 4187.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on LQDA. Wells Fargo & Company raised their price objective on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Oppenheimer set a $75.00 price objective on Liquidia in a research report on Friday. Raymond James Financial reiterated a “strong-buy” rating and set a $68.00 target price on shares of Liquidia in a research note on Thursday. Needham & Company LLC increased their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, BTIG Research increased their target price on Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and a consensus price target of $55.63.

Hedge Funds Weigh In On Liquidia

Hedge funds and other institutional investors have recently modified their holdings of the business. Caprock Group LLC acquired a new position in Liquidia during the 3rd quarter worth about $37,114,000. Apis Capital Advisors LLC acquired a new position in shares of Liquidia in the 3rd quarter valued at about $9,569,000. Farallon Capital Management LLC lifted its stake in shares of Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after purchasing an additional 4,326,876 shares during the period. GSA Capital Partners LLP lifted its stake in shares of Liquidia by 63.6% in the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after purchasing an additional 24,555 shares during the period. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Liquidia in the 3rd quarter valued at about $1,536,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).